For Manuscript Submission, Check or Review Login please go to Submission Websites List.
For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.
Prognostic and Predictive Markers for Treatment Decisions in Early Breast CancerStickeler E.
Universitätsfrauenklinik Freiburg, Germany Corresponding Author
Prof. Dr. med. Elmar Stickeler, Universitätsfrauenklinik Freiburg, Hugstetterstr. 55, 79106 Freiburg i.Br., Germany, Tel. +49 761 27031-480, Fax -690, email@example.com
Breast cancer clinically represents a heterogeneous disease. Over the last decades, the integration of prognostic and predictive markers in treatment decisions has led to a more individualized and optimized therapy. While prognosis describes the risk of disease recurrence and diseaserelated death after diagnosis without the influence of therapy, prediction illustrates the probability of efficacy or response of a specific therapeutic measure. The substantial decline in breast cancer mortality seen over the last 20 years is primarily due to the delivery of adjuvant systemic therapy. It is important that clinical decisions are made to minimize overtreatment, undertreatment, and incorrect treatment. Improved understanding of breast cancer biology together with the utilization of classical biomarkers and the identification of new markers or profiles is increasingly defining who should receive cancer therapy and what therapy offers the best efficacy. The molecular targets as the prerequisite for successful concepts of specific therapies like antiestrogens, antibodies, or small molecules, have therefore high clinical value in regards to prognosis as well as prediction.
© 2011 S. Karger AG, Basel